| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Urology [M. D. B., C. A. P., C. P. N. D.], Cancer Biology [H. K., K. I., E. L., I. J. F., C. P. N. D.], and Epidemiology [E. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Angiogenesis is essential for tumor progression and metastasis. It is mediated by the release of angiogenic factors by the tumor or host. We analyzed the expression of angiogenic factors by the prostate cancer cell line LNCaP and two derived variants, in vitro and in vivo, to determine whether metastatic cell lines express higher levels of these factors. The production of three angiogenic factors, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interleukin 8 (IL-8), by LNCaP and its variants, LNCaP-LN3 (highly metastatic) and LNCaP-Pro5 (slightly metastatic), was measured by ELISA. VEGF, bFGF, and IL-8 mRNA expression was determined in vitro by Northern blot analysis. VEGF mRNA expression was determined in vivo by in situ hybridization. VEGF and flk-1 protein expression and microvessel density of LNCaP cell tumors were quantified by immunohistochemistry. In vitro, VEGF production by LNCaP-LN3 (3.15 ± 0.04 pg/ml/103 cells) was significantly higher than those of both LNCaP (2.38 ± 0.34 pg/ml/103 cells) and LNCaP-Pro5 (1.67 ± 0.37 pg/ml/103 cells; P = 0.049 and 0.001, respectively). None of the three cell lines produced detectable levels of bFGF or IL-8 in vitro. In vivo, LNCaP-LN3 tumors exhibited higher levels of VEGF mRNA and protein (152.2 ± 28.5 and 200.5 ± 28.3) and of flk-1 protein (156.5 ± 20.6) and had higher microvessel density (16.4 ± 4.2) than either LNCaP tumors (89 ± 17.5, 173.3 ± 23.0, 124.6 ± 21.6, and 12.4 ± 3.5, respectively) or LNCaP-Pro5 tumors (63 ± 14.7, 141.2 ± 38.1, 126.1 ± 20, and 5.8 ± 2.2, respectively). In conclusion, metastatic human prostate cancer cells exhibited enhanced VEGF production and tumor vascularity compared with prostate cancer cells of lower metastatic potential. Thus, VEGF may play an important role in prostate cancer metastasis.
This article has been cited by other articles:
|
|
 |
|
  S. Araki, Y. Omori, D. Lyn, R. K. Singh, D. M. Meinbach, Y. Sandman, V. B. Lokeshwar, and B. L. Lokeshwar Interleukin-8 Is a Molecular Determinant of Androgen Independence and Progression in Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6854 - 6862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fang, Q. Zhou, L.-Z. Liu, C. Xia, X. Hu, X. Shi, and B.-H. Jiang Apigenin inhibits tumor angiogenesis through decreasing HIF-1{alpha} and VEGF expression Carcinogenesis, April 1, 2007; 28(4): 858 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yano, Y. Fujii, A. Iwai, Y. Kageyama, and K. Kihara Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells. Clin. Cancer Res., May 15, 2006; 12(10): 3003 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Kollmar, C. Scheuer, M. D. Menger, and M. K. Schilling Macrophage Inflammatory Protein-2 Promotes Angiogenesis, Cell Migration, and Tumor Growth in Hepatic Metastasis Ann. Surg. Oncol., February 1, 2006; 13(2): 263 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, J. Lee, S. Lu, C. A. Pettaway, and Z. Dong Blockade of Transforming Growth Factor-{beta} Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice Clin. Cancer Res., June 15, 2005; 11(12): 4512 - 4520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, P. W. Kantoff, J. Ma, M. J. Stampfer, and D. J. George Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1557 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nicholson, K. Gulding, M. Conaway, S. R. Wedge, and D. Theodorescu Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach Clin. Cancer Res., December 15, 2004; 10(24): 8728 - 8734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. De Larco, B. R. K. Wuertz, and L. T. Furcht The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8 Clin. Cancer Res., August 1, 2004; 10(15): 4895 - 4900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuniyasu, R. Ukai, D. Johnston, P. Troncoso, I. J. Fidler, and C. A. Pettaway The Relative mRNA Expression Levels of Matrix Metalloproteinase to E-Cadherin in Prostate Biopsy Specimens Distinguishes Organ-confined from Advanced Prostate Cancer at Radical Prostatectomy Clin. Cancer Res., June 1, 2003; 9(6): 2185 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sweeney, T. Karashima, S.-J. Kim, D. Kedar, B. Mian, S. Huang, C. Baker, Z. Fan, D. J. Hicklin, C. A. Pettaway, et al. Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production Clin. Cancer Res., August 1, 2002; 8(8): 2714 - 2724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Karashima, P. Sweeney, J. W. Slaton, S. J. Kim, D. Kedar, J. I. Izawa, Z. Fan, C. Pettaway, D. J. Hicklin, T. Shuin, et al. Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., May 1, 2002; 8(5): 1253 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Soker, M. Kaefer, M. Johnson, M. Klagsbrun, A. Atala, and M. R. Freeman Vascular Endothelial Growth Factor-Mediated Autocrine Stimulation of Prostate Tumor Cells Coincides with Progression to a Malignant Phenotype Am. J. Pathol., August 1, 2001; 159(2): 651 - 659. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. SALCEDO, J. H. RESAU, D. HALVERSON, E. A. HUDSON, M. DAMBACH, D. POWELL, K. WASSERMAN, and J. J. OPPENHEIM Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells FASEB J, October 1, 2000; 14(13): 2055 - 2064. [Abstract] [Full Text]
|
|
|
|
|
|
N. Koshikawa, K. Takenaga, M. Tagawa, and S. Sakiyama Therapeutic Efficacy of the Suicide Gene Driven by the Promoter of Vascular Endothelial Growth Factor Gene against Hypoxic Tumor Cells Cancer Res., June 1, 2000; 60(11): 2936 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuniyasu, P. Troncoso, D. Johnston, C. D. Bucana, E. Tahara, I. J. Fidler, and C. A. Pettaway Relative Expression of Type IV Collagenase, E-cadherin, and Vascular Endothelial Growth Factor/Vascular Permeability Factor in Prostatectomy Specimens Distinguishes Organ-confined from Pathologically Advanced Prostate Cancers Clin. Cancer Res., June 1, 2000; 6(6): 2295 - 2308. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, B. Y. Eve, S. J. Kim, P. Perrotte, M. D. Balbay, S. Yano, M. Bar-Eli, R. Radinsky, C. A. Pettaway, et al. Interleukin 8 Expression Regulates Tumorigenicity and Metastases in Androgen-independent Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 2104 - 2119. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. McMahon VEGF Receptor Signaling in Tumor Angiogenesis Oncologist, April 1, 2000; 5(90001): 3 - 10. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
